ClinicalTrials.gg
RecruitingNCT06890221IPENIPAUpdated Mar 26, 2025

Impact of PErioperative Nutrition Intervention on Bioimpedance Phase Angle (IPENIPA) In Breast Cancer Patients

An interventional study of B-Crobes intake complete nutrition and Placebo in Breast Cancer Early Stage Breast Cancer (Stage 1-3) and Mastectomy Patient, sponsored by University of Malaya. Recruiting at 1 site in Malaysia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by University of Malaya · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Breast Neoplasms with a site in Malaysia — 14 open to participants now, 27 under way, 19 of them phase 3. Breast Neoplasms · Malaysia.

Planned enrollment
47th of 59
114 · median 479
Started
2025
with 3 others
No phase
13 of 62
5 open now
Primary completion
2026-10
later than 9 of 26 live
Registered
58th of 62
by date
Lead sponsor
4 of 62
University of Malaya

Among the 62 studies in Breast Neoplasms with a site in Malaysia, this one is the 47th largest by planned enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 with no phase, reaches primary completion later than 9 of the 26 other live ones, and was the 58th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

14 of the 62 studies in Breast Neoplasms with a site in Malaysia are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Breast Neoplasms with a site in Malaysia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to measure the mean difference of phase angle after nutritional intervention in breast cancer patients. The main question it aims to answer is:

  1. Can perioperative nutrition interventions improve phase angle in relation to other bioimpedance parameters, handgrip strength and surgical outcomes in breast cancer population?

Researchers will compare oral nutritional supplement to a placebo to see if oral nutritional supplement can improve phase angle.

Participants will:

  1. Be randomized into either arm
  2. Take oral nutritional supplement or placebo according to the result of randomization for 7 days preoperatively and 30 days postoperatively
  3. Have their measurements (weight, height, phase angle, handgrip strength) done at least 7 days preoperative, 1 day preoperative and 30 days postoperative
03

Conditions studied

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)
  • Mastectomy Patient

Browse trials for

Keywords

  • bioimpedance phase angle
  • nutritional intervention
  • oral nutritional supplement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Histopathologically confirmed operable breast cancer
  • Aged 18 of years and above
  • Consented and scheduled for mastectomy

Exclusion criteria

Exclusion Criteria:

  • On enteral supplementation prior to the study
  • Lactose intolerance
  • Pregnant or lactating
  • Previous history of gastrectomy or small bowel resection surgery
  • Advanced breast cancer staging, presence of pacemaker, decompensated liver disease, end stage renal failure, uncontrolled diabetes, on therapy or complementary traditional medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
114 participants (estimated)

Study arms

  • Placebo comparator
    Cohort A

    Placebo

    Dietary Supplement: Placebo

  • Active comparator
    Cohort B

    Oral nutrition supplement

    Dietary Supplement: B-Crobes intake complete nutrition

Interventions

  • Dietary supplementB-Crobes intake complete nutrition

    Contains whey and plant based proteins, enriched with prebiotics and probiotics, Ca-Hmb, minerals and multivitamins.

    Also known as: Oral nutrition supplement

  • Dietary supplementPlacebo

    Contains full cream dairy milk

06

What researchers measure

Primary outcomes

  1. Mean difference of phase angle after nutritional intervention

    To measure the mean difference of phase angle between groups after nutritional intervention

    Time frame: From enrollment to 30 days post operation

Secondary outcomes

  1. Changes in handgrip strength

    To study the changes on handgrip strength, body composition by bioimpedance analysis (skeletal muscle mass, skeletal muscle mass index, fat free mass and fat mass) after nutritional interventions.

    Time frame: From enrollment to 30 days post operation

  2. Correlation of phase angle with bioimpedance analysis parameters

    To describe the correlation of phase angle with nutritional status, handgrip strength, and body compositions by bioimpedance analysis (Skeletal muscle mass, skeletal muscle mass index, fat free mass, and fat mass).

    Time frame: From enrollment to 30 days post operation

  3. Potential factors associated with postoperative complications

    To identify the potential factors associated with complications and readmission in 30-days post-mastectomy participants.

    Time frame: From enrollment to 30 days post operation

  4. Cutoff value of phase angle

    To identify the cutoff value of PA in relation to GLIM malnutrition, nutrition risk, and sarcopenia

    Time frame: From enrollment to 30 days post operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 19 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2025
First posted
Mar 21, 2025
StartActual
Mar 7, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06890221
Collaborators
B-Crobes Laboratory (M) Sdn Bhd
Responsible party
Soo Wai Yin (Medical Doctor, University of Malaya) — Principal investigator
First posted
Mar 21, 2025
Start date
Mar 7, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 26, 2025

Study contacts

Wai Yin Soo, MD
Contact
waiyin@ummc.edu.my
+60 16-365 8711

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion